AKT-IN-6

• CAT Number: I029300
• CAS Number: 1430056-54-4
• Molecular Formula: C22H20FN5O
• Molecular Weight: 389.43
• Purity: ≥95%
• Synonyms: 5-[2-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-1-oxo-3H-isoindol-5-yl]-1-methylpyrazole-4-carbonitrile
• InChI: InChI=1S/C22H20FN5O/c1-27-21(17(10-24)12-26-27)15-5-6-20-16(9-15)13-28(22(20)29)19(11-25)8-14-3-2-4-18(23)7-14/h2-7,9,12,19H,8,11,13,25H2,1H3/t19-/m0/s1
• InChIKey: QXRHOURHCGFDIM-IBGZPJMESA-N
• SMILES: CN1C(=C(C=N1)C#N)C2=CC3=C(C=C2)C(=O)N(C3)[C@@H](CC4=CC(=CC=C4)F)CN

AKT-IN-6（Cat No.:I029300）is a selective, orally bioavailable small-molecule inhibitor of AKT, a serine/threonine kinase involved in the PI3K/AKT/mTOR signaling pathway that regulates cell survival, growth, and metabolism. By targeting AKT, AKT-IN-6 blocks downstream signaling critical to tumor progression and chemoresistance. It has demonstrated potent antiproliferative activity in cancer cell lines with aberrant AKT activation, including PTEN-deficient and PI3K-mutant tumors. AKT-IN-6 is under investigation for its potential in treating solid tumors and hematological malignancies. Its favorable pharmacokinetics and target specificity make it a promising candidate for targeted cancer therapy development.